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Abstract
Interaction of leukocyte function associated antigen-1 (LFA-1) on T-lymphoctytes and intercellular
adhesion molecule-1 (ICAM-1) on epithelial cells controls leukocyte adhesion, spreading, and
extravasation. This process plays an important role in leukocyte recruitment to a specific site of
inflammation and has been indentified as a biomarker for certain types of carcinomas. Cyclo-(1,12)-
PenITDGEATDSGC (cLABL) has been shown to inhibit LFA-1 and ICAM-1 interaction via binding
to ICAM-1. In addition, cLABL has been shown to internalize after binding ICAM-1. The possibility
of using cLABL conjugated nanoparticles (cLABL-NP) as a targeted and controlled release drug
delivery system has been investigated in this study. The cLABL peptide was conjugated to a modified
Pluronic® surfactant on poly (DL-lactic-co-glycolic acid) (PLGA) nanoparticles. The cLABL-NP
showed more rapid cellular uptake by A549 lung epithelial cells compared to nanoparticles without
peptide. The specificity of ICAM-1 mediated internalization was confirmed by blocking the uptake
of cLABL-NP to ICAM-1 using free cLABL peptide to block the binding of cLABL-NP to ICAM-1
on the cell surface. Cell studies suggested that cLABL-NPs targeted encapsulated doxorubicin to
ICAM-1 expressing cells. Cytotoxicity assay confirmed the activity of the drug incorporated in
nanoparticles. Sustained release of doxorubicin afforded by PLGA nanoparticles may enable
cLABL-NP as a targeted, controlled release drug delivery system.
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1. Introduction
Interaction of leukocyte function associated antigen-1 (LFA-1) and intercellular cell adhesion
molecule-1 (ICAM-1) can play a critical role in tumor metastasis and progression [Yusuf-
Makagiansar et al., 2002], [Hopkins et al., 2004], [Wojcikiewicz et al., 2003], [McDawa et al.,
1998], [Dunehoo et al., 2006] and [Yusuf-Makagiansar et al., 2001]. ICAM-1 is expressed on
a variety of inflammatory and immune effector cells as well as endothelial cells, fibroblasts,
and epithelial cells [Melis et al., 1996]. ICAM-1 is also up-regulated on the surface of a variety
of lymphomas, melanomas, renal, pancreatic, bladder and lung carcinomas and/or their local
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vascular network [Melis et al., 1996]. The expression of ICAM-1 may be involved in the
regulation of tumor susceptibility to the activity of defensive cells. The upregulation of ICAM-1
expression on some types of carcinomas such as melanomas and lung carcinomas may be
followed by the extracellular release of soluble ICAM-1 (sICAM-1) [Melis et al., 1996]. The
sICAM-1 could interfere with the interaction of surface ICAM-1 and immune cells such as
natural killer (NK) cells or lymphocyte activated killer (LAK) cells by competition, leading to
the reduction of cancer cell exposure to these protective cells [Melis et al., 1996]. Shedding of
sICAM-1 in the extracellular space has been proposed as one of the mechanisms that tumor
cells use to escape cell-mediated cytotoxicity [Melis et al., 1996].
A cyclic peptide, cyclo-(1,12)-PenITDGEATDSGC (cLABL), derived from the I-domain of
the αL-subunit of LFA-1 integrin has been shown to impair LFA-1/ICAM-1 interaction by
binding to the D1 domain of ICAM-1. This peptide specifically inhibited homotypic and
heterotypic T-cell adhesion to epithelial and endothelial cell monolayers by disrupting the
LFA-1/ICAM-1 interaction [Anderson and Siahaan, 2003a], [Anderson et al., 2004],
[Anderson and Siahaan, 2003b], [Yusuf-Makagiansar and Siahaan, 2001] and [Yusuf-
Makagiansar et al., 2007]. In addition to its receptor binding characteristics, cLABL displayed
receptor mediated endocytosis, insinuating a possible use as a targeting moiety for intracellular
drug delivery [Yusuf-Makagiansar and Siahaan, 2001]. Accordingly, cLABL conjugated
nanoparticles were proposed to be a promising anti-cancer drug delivery system targeting
ICAM-1.
Recently, monoclonal antibodies have become crucial therapeutic agents against a wide range
of cancers. However, autoimmune reactions and short half-lives are often encumbrances for
immunotherapy using monoclonal antibodies [Tibetts et al., 2000], [Wofsy, 1985] and [Huang
et al., 2005]. Peptides and small molecule inhibitors may offer similar therapeutic interventions
by acting as a targeting ligand to proteins on the cell surface [Yusuf-Makagiansar et al.,
2002]. Furthermore, in comparison to monoclonal antibodies, cyclic peptides have been shown
to offer improved physicochemical stability and may even improve selectivity to the targeted
site [Yusuf-Makagiansar et al., 2002] and [Yusuf-Makagiansar et al., 2001].
The utmost ambition of pharmaceutical therapy is to deliver the drug carriers to a specific
therapeutic site of action with a triggered or sustained drug release. Advantages of this modality
could include a decrease in adverse effects, lower toxicity, an increase in the efficacy of the
therapeutic agent and a reduction in the frequency of administration. Polymeric nanoparticles
(NP) possess some advantages over other formulations in terms of stability and feasibility of
modulating the drug release profile by controlling polymer degradation [Avgoustakis, 2004]
and [Guerrouache et al., 2006]. In addition, this delivery system permits functional group
modification on the nanoparticle surface without compromising the activity of the drug carried.
In this study, cLABL-conjugated poly (DL-lactic-co-glycolic acid) nanoparticles (cLABL-NP)
targeting ICAM-1 on A549 lung epithelial cells have been formulated and characterized.
Binding and internalization studies have demonstrated that nanoparticles can be targeted to
these epithelial cells via ICAM-1 and can be internalized into the cells rapidly. The cellular
internalization was confirmed by utilizing fluorescence markers and microscopy. Interestingly,
the results indicated that cLABL-NP trafficked to lysosomes and escaped lysosomal
sequestration. Targeting and drug release studies of nanoparticles encapsulating doxorubicin
(DOX-NP) suggested that PLGA nanoparticles targeted by cLABL localized this drug within
A549 cells to offer sustained release. The IC50 of nanoparticles encapsulating doxorubicin,
both conjugated and not conjugated with peptide compared to that of free doxorubicin HCl
were reported. Ultimately, cLABL-nanoparticles may be aerosolized to provide a targeted anti-
cancer drug delivery system directly to the pulmonary epithelium.
Chuda et al. Page 2













2. Materials and Methods
2.1 Materials
Poly(DL-lactic-coglycolic acid) (50:50) with terminal carboxylate group (PLGA, inherent
viscosity 0.22 dL/g, Mw ~ 20 kDa and 0.67dL/g, Mw ~90 kDa) was purchased from LACTEL
Absorbable Polymers International (Pelham, AL, USA). Pluronic®F-127, Texas Red Dextran
(10,000 Mw, lysine fixable) and 4′,6-diamidino-2-phenylindole, dilactate (DAPI, dilactate)
were purchased from Invitrogen Molecular Probes, Inc. (Carlsbad, CA, USA). 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide
(sulfo-NHS) were purchased from Thermo Fisher Scientific Inc. (Rockford, IL, USA)
Coumarin-6 was obtained from Polysciences, Inc. (Warrington, PA, USA). Doxorubicin HCl
for injection was provided by Novaplus (Irving, TX, USA). Dialysis membrane (MWCO
100,000) was purchased from Spectrum laboratory Products Inc. (Rancho Dominguez, CA,
USA). F-12K medium and A549 cell line were obtained from American Type Culture
Collection (Manassas, VA, USA). Recombinant, Human, Tumor Necrosis Factor-α (TNF-α)
was purchased from Promega (Madison, WI, USA). Human Interferon gamma was purchased
from Roche Diagnostics Corporation (Indianapolis, IN, USA), 3,3′,5,5′-Tetramethylbenzidine
(TMB) was obtained from Sigma (St. Louis, MO, USA). Monoclonal anti-human CD54
(ICAM-1) Domain D1 was purchased from Ancell (Bayport, MN, USA) and Horseradish
Peroxidase-Conjugated Goat Anti-Mouse IgG was obtained from Cayman Chemical (Ann
Arbor, MI, USA). CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS)
was purchased from Promega (Madison, WI, USA)
2.2 Methods
Pluronic®F-127 functional group modification—Terminal hydroxyl groups on
Pluronic®F-127 were converted to carboxyl groups according to the following procedure
[Guerrouache et al., 2006]. Pluronic®F-127 (2 g) was dissolved in tetrahydrofuran (THF, 60
ml). Then 4-dimethylaminopyridine (DMAP, 98 mg), triethylamine (108 μl) and succinic
anhydride (800 mg) were added. The mixture was stirred for 48 hr at room temperature. The
solution was dried by rotary evaporation, and, was then dissolved in carbon tetrachloride (30
ml). The excess succinic anhydride was removed by filtration. The Pluronic®F-127-COOH
was purified by precipitation with ice-cold diethylether. The product was identified by 1H NMR
sepctroscopy (Bruker AVANCE 400 MHz spectrometer) and FTIR spectroscopy (ABB
Bomem MB series).
Preparation of PLGA nanoparticles encapsulating coumarin-6—Nanoparticles
encapsulating a fluorescence marker, coumarin-6, were formulated using a solvent
displacement method [Avgoustakis, 2004]. In brief, PLGA, inherent viscosity 0.22 dl/g or 0.67
dl/g) was dissolved in trifluoroethanol (TFE, 18 mg/ml) containing coumarin-6 (95 μg). The
solution was slowly transferred to a water phase containing surfactant; 0.1% Pluronic®F-127-
COOH (35 ml) under mild stirring (250 RPM). The nanoparticles were spontaneously formed
due to the rapid removal of TFE. Excess surfactant was removed by dialysis against a 0.2%
mannitol solution for 48 hr.
Preparation of PLGA nanoparticles encapsulating doxorubicin—Doxorubicin HCl
for injection (2 mg/ml) was lyophilized and neutralized using triethylamine (108 μmol). The
non-aqueous form of doxorubicin was extracted using methylene chloride and evaporated
[Kim et al., 2008]. In brief, PLGA (0.22 dl/g or 0.67 dl/g) in acetone solution (18 mg/ml) was
mixed with 1.8 mg of the purified doxorubicin. The solution was infused (17.5 ml/hr) into 10
ml of 0.1% Pluronic®F-127-COOH (250 rpm) to allow the formation of nanoparticles
encapsulating doxorubicin (DOX-NP). Nanoparticles were collected by centrifugation (15,000
rpm, 40 min) and washed three times. The nanoparticles encapsulating doxorubicin conjugated
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with cLABL (cLABL-DOX-NP) was prepared using the method described above. The
encapsulation efficiency was determined by centrifugation (13,000 rpm, 40 min) of the DOX-
NP or cLABL-DOX-NP suspension (200 μl) by collecting the pellet and dissolving in DMSO
(200 μl). Doxorubicin content was analyzed by fluorescence spectroscopy (Spectramax M5,
ex: 500 nm, em: 600 nm).
Conjugation of cLABL peptide to PLGA-nanoparticles—A Pluronic®F-127-COOH
coated PLGA nanoparticles (1.5 mg/ml) suspension was buffered using 2-(N-morpholino)
ethanesulfonic acid (MES) pH 6.5. Nanoparticles were then incubated with 100 mM 1-Ethyl-3-
[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 50 mM N-
hydroxysulfosuccinimide (sulfo-NHS) for 15 min [Cheng et al., 2007]. The activated carboxyl
terminus of Pluronic® F127-COOH on the surface of nanoparticles was allowed to react with
the amino terminus of the cLABL peptide (80 μM) at least 6 hr at room temperature. Conjugated
NP were collected by centrifugation (10,000 rpm, 10 min) and washed three times with purified
water. Size and charge of NP and cLABL-NP were characterized using dynamic light scattering
(ZetaPALS, Brookhaven instrument Inc.). The amount of free cLABL after the reaction was
quantified by gradient reversed phase HPLC (SHIMADZU) using a C18 column. The HPLC
consisted of SCL-10A SHIMADZU system controller, LC-10AT VP SHIMADZU liquid
chromatograph, SIL-10A XL SHIMADZU autoinjecter set at 10 μl injection volume,
DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-Vis detector
(220 nm). The HPLC-UV system was controlled by a personal computer equipped with
SHIMADZU class VP Software. All separations were carried out using a Vydac® HPLC
column Protein and Peptide C18 column. Gradient elution was carried out at constant flow of
1 ml/min, from 100% A to 0% A (corresponding to 0% B to 100% B) for 15 min, followed by
an isocratic elution at 100% B for 3 min. Mobile phase compositions were (A) acetronitrile-
water (5:95) with 0.1% TFA (B) acetonitrile–water (90:10, v/v) with 0.1% trifluoroacetic acid
(TFA). At the end of each analysis, the cartridge was re-equilibrated at 1 ml/min flow rate for
13 min with A. The density of peptide on the surface of nanoparticles was calculated from the
total surface area assuming a normal Guassian particle size distribution.
Drug release study of nanoparticles encapsulating doxorubicin—The release of
doxorubicin from cLABL-DOX-NP or DOX-NP was investigated using 0.1M acetate buffer
pH 4 and phosphate buffer pH 7.4 as dissolution media. One milliliter of DOX-NP (4 mg/ml)
or five hundred microliters of cLABL-DOX-NP (4 mg/ml) were placed in the dialysis
membrane (MwCO 10,000) immersed in 100 ml and 50 ml of buffer solution, respectively and
were shaken at 100 rpm, 37°C [Missirlis et al., 2006]. At predetermined time points, the
dialysate was sampled and the amount of released doxorubicin was determined using
fluorescence spectroscopy (ex; 500 nm, em; 600 nm).
Cytotoxicity assay—The CellTiter 96® AQ Non-Radioactive Cell Proliferation Assay(a) is
a colorimetric method used to determine the viability of cells in this cytotoxicity study. ICAM-1
up-regulated A549 cells (80,000 cells/ml) were incubated with cLABL-DOX-NP or DOX-NP
for 3 hr and then were washed three times with PBS. Cells were incubated in cell culture
medium for 20 hr to allow the sustained release of the drug. For a control experiment, cells
were incubated with doxorubicin HCl for 20 hr. After incubation, cells were washed three times
with PBS. The solution composed of tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS and an electron coupling
reagent (phenazine methosulfate; PMS) (20 μl) was added into each well containing 100 μl of
cell culture medium. The plate was then incubated at 37°C, 5%CO2 for 4 hr. The quantity of
formazan product was determined by the amount of 490 nm absorbance.
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Determination of ICAM-1 expression on A549 cells using Enzymed-Linked
Immunosorbent Assay (ELISA)—A549 carcinomic human alveolar basal epithelial cells
were cultured in F12K medium with 10% fetal bovine serum (FBS) and 1% Penicillin-
Streptomycin (10,000 U/ml) 37°C, 5% CO2. Cell monolayers were incubated with TNF-α
(1,000 U/ml) or IFN-γ (100 U/ml) for 48 hr to activate the up-regulation of ICAM-1 on the
cell surface [Konno et al., 2002]. ICAM-1 expression was measured using an indirect ELISA.
A549 cells (8 × 105 cells/ml) were seeded in a 96 well-plate. Cells were fixed by using 2%
formaldehyde in PBS (100 μl/well) and incubated at room temperature for 1 hr. Cells were
washed with PBS (200 μl/well) and then non-specific adsorption was blocked by incubating
with 1% BSA in PBS (120 μl/well) for 30 min at room temperature. After washing with PBS,
monoclonal anti-human CD54 (ICAM-1) domain D1 (120 μl/well) was added and incubated
1 hr at 37°C. Goat anti-mouse IgG HRP (100 μl/well) was then added after washing with PBS
and incubated for 1 hr at 37°C. Cells were washed three times with PBS and incubated with
3,3′,5,5′ tetramethylbenzidine as the substrate for 15 min at room temperature. The enzyme-
substrate reaction was stopped by adding 1 N sulfuric acid. The absorbance was obtained by
UV spectroscopy (Spectramax M5; λmax 450 nm)
Binding and Uptake of Nanoparticles by A549 cells—A549 cell monolayers were
incubated with TNF-α (1,000 U/ml) for 48 hr to over express ICAM-1 receptors. Cells were
then washed three times with serum free F12K and then incubated with nanoparticles (with or
without cLABL conjugated) suspended in serum free medium (0.5 mg/ml). Cells were
incubated with nanoparticles for different time intervals to observe the uptake kinetics of
particles. After incubation, cells were washed three times with ice-cold PBS and lysed with
0.5% Triton X-100 in 0.2 M NaOH [Davda and Labhasetwar, 2002]. cLABL-NP and NP
associated with the cells were detected and compared using a fluorescence plate reader
(Spectramax M5; ex: 450 nm, em: 500 nm) [Koefod and Mann, 1991].
Inhibition of cLABL-NP binding to ICAM-1—Various concentrations of free cLABL
peptide or anti-ICAM-1 mAbs were incubated with activated A549 cells for 30 min, 37°C, 5%
CO2. Cells were then washed three times with serum free media and incubated with cLABL-
NP or nanopartilces without peptide for 1 hr at the same condition. Cells were washed three
times with ice-cold PBS, lysed with 0.5% Triton X-100 in 0.2 M NaOH. cLABL-NP and NP
content bound to the cell surface or internalized into the cells were determined and compared
by fluorescence spectroscopy (Spectramax M5; ex: 450 nm, em: 500 nm).
Intracellular trafficking of cLABL-NP to lysosomes—ICAM-1 on A549 cells were
activated using (1,000 U/ml) TNF-α for 48 hr. Lysosomes were labeled with Texas Red dextran
(10,000 Mw, lysine fixable) to indicate the location of lysosomes. Texas red dextran prepared
in serum free F12K (1 mg/ml) was incubated with activated A549 cells for 2 hr. Cells were
then washed with serum free media for three times and further incubated with serum free media
for up to 12 hr in order to chase the red fluorescent dye to localize in lysosomes [Hirota et al.,
2004] and [Duvvuri and Krise, 2005]. Cells were then incubated in the presence of cLABL-
NP or NP containing the green fluorophore, coumarin-6, for 10 min. Cells were washed three
times and incubated with serum free medium for each time point. After washing with ice-cold
PBS, cells were fixed with 4% formaldehyde solution. Fluorescence emissions of nanoparticles
and lysosomes were observed using FITC and rhodamine filter sets, respectively (Nikon
Eclipse 80i microscope equipped for epifluorescence). Micrographs were captured using an
Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ). Colocalizations of nanoparticles and
lysosomes were analyzed by Metamorph, version 6.2 (Universal Imaging Corp., West Chester,
PA)
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Intracellular trafficking of doxorubicin and nanoparticles encapsulating
doxorubicin—TNF-α activated A549 cells were incubated with free doxorubicin (0.5 mg/
ml) or doxorubicin encapsulated in nanoparticles conjugated with cLABL (cLABL-DOX-NP)
or without cLABL (DOX-NP) (3.8 mg/ml) for 1 hr (for 1 hr observation) and 3 hr (for 3 hr, 8
hr and 24 hr observation). Cells were then washed three times with ice-cold PBS and incubated
with media with serum for each time period (8 hr and 24 hr). Cells were fixed with 4%
paraformaldehyde. Nuclei were labeled with DAPI dilactate (blue) (300 nM, ex: 358 nm, em:
461 nm) for 5 min at 37°C, 5%CO2. Micrographs were taken using the Nikon Eclipse
microscope.
For some studies, nanoparticles encapsulating doxorubicin contained the fluorophore,
coumarin-6, to indicate the location of particles in the cells. cLABL-DOXNP and DOX-NP
encapsulating coumarin-6 were incubated with cells for each time period (15 min, 30 min, 1
hr and 3 hr). Cells were washed three times with ice-cold PBS and fixed with 4%
paraformaldehyde. Nuclei were labeled with DAPI dilactate (blue) (300 nM, ex: 358 nm, em:
461 nm) for 5 min at 37°C, 5%CO2. Micrographs were taken using the Nikon Eclipse
microscope.
Statistical analysis—Statistical evaluation of data was performed using an analysis of
variance (one-way ANOVA). Newman–Keuls was used as a post-hoc test to assess the
significance of differences. To compare the significance of the difference between the means
of two groups, the t-test was performed; in all cases, a value of p < 0.05 was accepted as
significant.
3. Results and Discussion
Preparation of Carboxylated Pluronic® F-127
The hydroxyl groups of Pluronic® F-127, HO(C2H4O)100(C3H6O)65(C2H4O)100H [Kabanov
et al., 2002], were converted to carboxyl groups to facilitate the conjugation reaction of this
surfactant with the terminal amine of cLABL peptide. The 1H NMR spectrum displayed the
absorption of methylene protons adjacent to the succinic moiety at δ = 4.1 ppm and the proton
of the carboxylic acid at δ = 12 ppm (Supplementary Fig. 1) [Guerrouache et al., 2006]. The
COOH formation was confirmed by FTIR spectroscopy. The FTIR spectrum showed a strong
C=O stretching absorption at 1,720 cm−1 and a very broad, strong absorption at 3,500 cm−1,
which indicated the appearance of the hydroxyl of carboxylic acid (Supplementary Fig. 2).
These results confirmed the formation of carboxylated Pluronic® F-127.
Preparation of PLGA nanoparticles encapsulating coumarin-6
PLGA nanoparticles were prepared by a spontaneous solvent displacement method using
carboxylated Pluronic® F-127 as an anionic surfactant. Dynamic light scattering showed that
the size of nanoparticles encapsulating coumarin-6 was approximately 225 nm in diameter with
a low polydispersity suggesting a narrow size distribution, and that the zeta potential value was
about −45 mV (Table 1). An increase in size and negative charge of nanoparticles after
conjugation with cLABL peptide was observed, which was expected due to the pI value of
cLABL peptide (pI−3.5). The size and charge of nanoparticles encapsulating coumarin-6 were
comparable when either form of PLGA (0.22 dl/g or 0.67 dl/g) was used to formulate
nanoparticles. The encapsulation efficiencies of coumarin-6 in both nanoparticles were
reported in Table 2. As expected, the encapsulation efficiencies were diminished in both types
of PLGA after the conjugation reaction.
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Preparation of PLGA nanoparticles encapsulating doxorubicin
A variety of mAbs have been identified for immunotherapy against a wide range of cancers
[Kurosawaa et al., 2008]. Peptides that can target the immunoglobulin receptor offer a simple
alternative to mAbs. The cLABL peptide itself has a therapeutic effect, however, potency may
be improved by using this ligand to target drug loaded nanoparticles. Nanocarriers often exhibit
various benefits such as prolonged circulation and tumor localization via the enhanced
permeability and retention effect [Kim et al., 2008]. Doxorubicin, one of the most widely used
anti-cancer drugs, was incorporated in nanoparticles in this study.
Nanoparticles encapsulating doxorubicin was prepared and characterized in this study. The
size and charge of doxorubicin loaded nanoparticles increased after conjugation with the
cLABL peptide (Table 1). The encapsulation efficiency of doxorubicin in nanoparticles was
acceptable at 41 ± 4.8 % and 51 ± 7.6% when PLGA Mw~20 KDa and ~90 KDa were used to
formulate nanoparticles, respectively (Table 2). After the conjugation reaction, the
encapsulation efficiency was reduced by ~54 and ~47% when PLGA Mw~20 KDa and ~90
KDa were reacted with cLABL, respectively. However, other studies have suggested that the
encapsulation efficiency may be increased by an ester linkage of the carboxylic acid end group
of PLGA and the hydroxyl group of doxorubicin, which results in retention of doxorubicin
during the nanoparticle preparation procedure [Yoo et al., 2000]. Ultimately, doxorubicin
serves as a convenient fluorescent marker for these studies and more hydrophobic drugs would
likely offer improved encapsulation efficiencies.
Conjugation of cLABL peptide on the surface of nanoparticles
The efficiency of the coupling reaction between the amino group of cLABL and the carboxyl
of Pluronic® F-127-COOH coated on nanoparticles was determined. The amounts of free
cLABL were analyzed (prior to and after the reaction) by reversed phase HPLC. The peptide
density on the surface of nanoparticles encapsulating coumarin-6 was calculated from the total
surface area assuming a normal Guassian particle size distribution [Zhang et al, 2008] The
density of peptide on both types of nanoparticle surfaces (0.22 dl/g and 0.67 dl/g) were
comparable (Table 3). The calculation showed a higher density of cLABL conjugated
compared to previous studies [Zhang et al., 2008] which conjugated the peptide with
polyethylene glycol (PEG)-modified poly(ethylene-alt-maleic acid) on the nanoparticle
surface. This may be due to the more available carboxyl groups of Pluronic® -COOH coated
on the nanoparticle surface. Therefore, the use of modified Pluronic® may reduce the steps of
the conjugation reaction, and also increase the density of peptide conjugated [Zhang et al.
2008].
In vitro drug release study of nanoparticles encapsulating doxorubicin
Generally the release of doxorubicin from the drug carriers was pH dependent probably due
to the increase in solubility of doxorubicin at mildly acidic pH [Gillies and Frechet, 2005] and
[Kataoka et al., 2000]. The release of the drug at pH 4 and 7.4 were determined for doxorubicin
encapsulated in cLABL-NP and untargeted NP. These pH values were selected to represent
extracellular and lysosomal pH values. The drug release from PLGA nanoparticles was
determined using PLGA inherent viscosity 0.67 dl/g in acetate buffer at pH 4 and phosphate
buffer at pH 7.4. The release of doxorubicin from cLABL-DOX-NP followed a biphasic profile
regardless of pH (Fig 8). The release profile was characterized by a rapid release in the initial
stage. The release of doxorubicin began with an initial burst of 35 ± 1.7% and 34 ± 2.8% from
cLABL-DOX-NP at pH 4 and 7.4, respectively, in the first three hours of the study. Drug burst
may result from the large surface to volume ratio of nanoparticles and from rapid loss of drug
via diffusion through the polymer matrix at or near the particle surface. The initial burst phase
was followed by slow and sustained release. The slower phase likely resulted from continued
diffusion through the PLGA matrix [Holgado et al., 2008].
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A higher amount of doxorubicin was released from unmodified PLGA nanoparticles at pH 4
compared to at pH 7.4. The release profile of the drug from NP without peptide showed a
greater initial burst at pH 4 and pH 7.4 in a comparison to the conjugated peptide, i.e., 76 ±
4.4% vs 35 ± 1.7 % and 53 ± 2.7% vs 34 ± 2.8%, respectively, in first three hours. The rapid
release at the initial state may be due to the high aqueous solubility of the protonated form of
doxorubicin at the glycosidic amine in a low pH medium [Gillies and Frechet, 2005] and
[Kataoka et al., 2000]. Interestingly, doxorubicin was released from cLABL-NP in a higher
amount in higher pH medium (pH 7.4) compared with medium pH 4 as shown in Fig. 8 The
more increasing release of doxorubicin from cLABL-DOX-NP in higher basic pH may have
resulted from the agglomeration of the nanoparticles during the release study at pH 4. At higher
pH, cLABL has higher negatively charge compared to at more acidic pH (pI~3.5). The high
amount of doxorubicin released at this pH should be considered for drugs delivered by this
nanoparticle formulation. The cLABL-NP would need to rapidly localize to the lung epithelium
expressing ICAM-1 to avoid premature drug release supporting the pulmonary delivery as a
choice of the route of administration. Furthermore, selection of more hydrophobic
chemotherapeutic agents may be appropriate.
Cytotoxicity assay
The cytotoxicity of doxorubicin HCl, cLABL-DOX-NP and DOX-NP to A549 cells was
evaluated by using MTS assay. The IC50 value of free doxorubicin, doxorubicin released from
cLABL-NP and doxorubicin released from unconjugated NP was 60, 30 and 53 μg/ml,
respectively. The cytotoxicity of doxorubicin released from nanoparticles was comparable to
that of free doxorubicin. The concentrations of doxorubicin in nanoparticles were calculated
from the drug loading adjusted by the encapsulation efficiency. The relative IC50 value of
doxorubicin from each formulation suggested that the activity of drug encapsulated in
nanoparticles were not affected by the encapsulation and conjugation reaction. The IC50 values
of cLABL-DOX-NP and DOX-NP were 3.1 and 3.3 mg/ml, respectively. PLGA NP without
doxorubicin did not show any cytotoxicity up to 10 mg/mL (data not shown) suggesting that
the doxorubicin is slowly released from these non-cytotoxic carriers. Modification of PLGA
NPs with cLABL did not negatively affect the cell viability
Uptake and Internalization of Nanoparticles
Pro-inflammatory cytokines such as TNF-α have previously been shown to upregulate the
expression of ICAM-1 [Konno et al., 2002]. Incubating A549 cells with TNF-α (1,000 U/ml)
or IFN-γ (100 U/ml) resulted in about 5 fold and 4 fold increase of ICAM-1, respectively, as
determined by ELISA (Fig. 1). This result confirmed the overexpressed of ICAM-1 and
validated the use of this cell line as an inflammatory epithelial cell model. The binding and
uptake of cLABL-NP to A549 cells were found to be significantly more rapid compared to
untargeted NP. The increasing fluorescence intensity demonstrated the increasing amount of
nanoparticles bound or taken up by cells (Fig. 2). In the presence of cLABL-NP, the
fluorescence intensity was 2.3 fold higher compared to the control nanoparticles after 5 min
of incubation. The difference in the uptake extent diminished when the incubation time
increased. This result may indicate saturation of ICAM-1 receptors. In addition, A549 cells
have been shown to endocytose nanoparticles extensively, which may explain the significant
uptake of unlabeled nanoparticles [Kimberly and Kenneth, 2001].
A blocking study demonstrated the inhibition of cLABL-NP binding to ICAM-1 by free
cLABL and anti-ICAM-1 mAbs. The depletion of fluorescence intensity showed that the
binding of cLABL-NP to ICAM-1 was impeded when free cLABL was incubated with cells
first (Fig. 3A) suggesting a specific binding of cLABL-NP to ICAM-1 on A549 cells [Muro
et al., 2005]. In addition, a decrease in fluorescent intensity was shown when anti-ICAM-1 was
pre-incubated with the cells; however, the difference was not statistically significant (Fig. 3B).
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Intracellular trafficking of cLABL-NP to lysosomes
The cLABL-NPs were observed to rapidly internalize into A549 cells after the 15 min
incubation period. This rapid internalization of ICAM-1 targeting nanoparticles agreed with
internalization of nanocarriers targeted using anti-ICAM-1 monoclonal antibodies studied by
Muro et al (15-30 min) [Muro et al., 2003]. The binding and internalization of cLABL-NP
were likely induced by the multimeric nature of ICAM-1 ligands (cLABL) on the nanoparticle
surface [Muro et al., 2003]. In this study, cLABL-NPs were observed to accumulate in
lysosomes at 1 hr after binding to the cell surface. Subsequently, the colocalization of cLABL-
NP with lysosomes steadily decreased until no colocalization was observed at 24 hr (Fig. 4).
The intracellular trafficking kinetics of cLABL-NP may have advantages in comparison to
unconjugated NP or free drug. Muro et al. report that the cLABL-NP spend more time in the
early endosomes as described in the trafficking study of anti-ICAM-1 nanoparticles into
HUVECs. [Muro et al., 2003]. The result in this study revealed that internalized cLABL-NP
may traffic away from lysosomes. The removal of cLABL-NP, from lysosomes was probably
not due to disruption of the lysosomes because there was no change in the distribution of Texas
Red conjugated dextran during 24 hr of incubation observed in this study [Panyam et al.,
2002]. Overall, the results suggested that the lysosomal degradation of cLABL-NP may be less
pronounced by this intracellular trafficking pathway. The therapeutic activity of cytotoxic
drugs may also be prolonged by avoiding enzymatic degradation in the lysosomes by lysosomal
sequestration.
Untargeted nanoparticles merged with lysosomes at 2 hr after incubation but to a lower extent
compared to ICAM-1 targeted NPs (Fig. 5). This result suggested that nanoparticles without
peptide may be taken up more slowly than targeted NP which agrees with the result of our
uptake study described above. The accumulation of untargeted NPs was also not observed at
a later time point of incubation. A mechanism of escape of PLGA-NP has been proposed
previously by the fact that PLGA-NP may undergo charge neutralization during trafficking
[Panyam et al., 2002]. The removal of particle charge was suggested to mediate membrane
association leading to the escape of nanoparticles [Panyam et al., 2002].
Intracellular trafficking of doxorubicin and cLABL-NP encapsulating doxorubicin
The cLABL-DOX-NP and DOX-NP were incubated with A549 cells to study intracellular
trafficking. Intracellular localization of free doxorubicin, cLABL-DOX-NP and DOX-NP were
investigated using fluorescence microscopy. Free doxorubicin, which is fluorescent (red), was
used as a control. The nuclei of cells were stained with the blue fluorescence dye, DAPI. The
photographs of cLABL-DOX-NP, DOX-NP and free doxorubicin were combined with the
stained nuclei to observe the colocalization of the doxorubicin and the nuclei. The merged
micrographs showed that free doxorubicin displayed rapid colocalization with the nuclei of
A549 cells (in 1 hr) as expected (Fig. 6A). Cells exposed to cLABL-DOX-NP exhibited a small
degree of colocalization of doxorubicin and nuclei in some cells during the first hour of the
study (Fig. 6B). This result suggested that a small amount of doxorubicin may be released and
localized in the nuclei as indicated by the faint purple color in the nuclei. The colocalization
of the drug and the nuclei shown from the color combination was further observed until 24 hr.
In contrast, this colocalization of doxorubicin and the nuclei was observed at later time (3 hr)
for the untargeted NP (Fig.6C). Doxorubicin was also observed to localize within the nuclei
until 24 hrs. In a comparison to free doxorubicin, doxorubicin encapsulated in nanoparticles
was slowly released and localized in the nuclei more gradually after cellular uptake. This result
provided evidence to the capability of nanoparticles to offer targeted, intracellular delivery of
this cytotoxic drug and suggested the prolonged retention of doxorubicin and sustained release
of drug from nanoparticles.
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Also, the yellow dots in overlaid pictures of cLABL-NP or NP (green) and doxorubicin (red)
confirmed the retention of doxorubicin in nanoparticles encapsulating coumarin (green) (Fig.
7A and B). The colocalization of dye and drug suggested that the images show the uptake of
nanoparticles containing drug and not released drug.
4. Conclusion
This work has aimed to further develop the role of cLABL as a means of targeting PLGA NP
to a molecular marker, ICAM-1, associated with inflammatory diseases and cancer. Targeted
nanoparticles are of increasing interest because they may allow a reduction of adverse side
effects and increase the efficacy of a drug by localizing it to the desired site of action. PLGA
has advantages over other polymers due to its biodegradability, biocompatibility and approval
by the FDA. Besides, PLGA NPs have provided controlled drug release in several studies,
which lowered observed side effects [Avgoustakis, 2004], [Keegan et al., 2004], [Kim et al.,
2008] and [Panyam et al., 2002]. Here, PLGA nanoparticles targeting the immunologically
active receptor, ICAM-1, were formulated by attaching the cLABL peptide to the nanoparticle
surface. The cLABL-NP displayed specific binding to ICAM-1 compared to non-targeted NP.
The cLABL-NPs were also more rapidly taken into A549 lung epithelial cells induced to
overexpress ICAM-1. Intracellular trafficking studies showed that cLABL-NP accumulated in
lysosomes for 1 hr and then left after 3 hr. Conversely, untargeted NP accumulated in lysosomes
more slowly (2 hr), and also left at a later time point. cLABL-NP encapsulating doxorubicin
also accumulated quickly in A549 cells. Drug release studies indicated that the cLABL-NP
formulated with a high Mw PLGA exhibited sustained drug release that depended on pH.
Finally, the cytotoxicity study of cLABL-NP and NP compared to free doxorubicin HCl
showed similar IC50 values suggesting that the activity of the drug released from nanoparticles
was retained. These studies verified that cLABL can target nanoparticles to lung epithelial cells
to deliver chemotherapeutics and provide controlled release drug delivery. The effectiveness
of targeted delivery in vivo must be inquired in future studies.
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(A). Effect of IFN-γ on A549 ICAM-1 expression. Confluent monolayers of A549 cells were
incubated 48 hr with IFN-γ (0-600 U/ml), and ICAM-1 expression was determined by ELISA.
Data were presented as mean ± S.D. (n = 3). (B) Expression of ICAM-1 activated by TNF-α
(1,000 U/ml) was significantly higher than IFN-γ (100 U/ml) and non-activated A549 cells.
Data are presented as mean ± S.D. (n = 3). *** indicates p < 0.001.
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Fluorescent intensity of cLABL-NP was significantly higher than untargeted NP for short
incubation periods. Cells were incubated with nanoparticles (0.5 mg/ml) for different time
intervals to observe the uptake of particles. Cell lysates were analyzed by fluorescence
spectroscopy and data presented are mean ± S.D. (n = 3). *** indicates p < 0.001 and * indicates
p < 0.05.
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(A). The depletion of fluorescence intensity showed the inhibition of cLABL to the binding
and internalization of cLABL-NP. Free cLABL peptide was incubated with cells for 30 min.
Cells were then washed and incubated with nanoparticles for 1 hr. Cell lysates were analyzed
by fluorescence spectroscopy and data presented are mean ± S.D. (n = 3). (B) Anti-ICAM-1
pre-incubated with cells reduced the fluorescent intensity but the difference was not statistically
significant. Cells were treated with anti-ICAM-1 for 30 min, and then incubated with
nanoparticles for 1 hr. Cell lysates were analyzed by fluorescence spectroscopy and data
presented are the mean ± S.D. (n = 3). *** indicates p < 0.001 and ** indicates p < 0.01.
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Localization of cLABL-NP with lysosomes (red) was observed at 1 hr after incubation with
cells. The extent of colocalization decreased thereafter. Cells were incubated in the presence
of cLABL-NP for 10 min, washed and incubated with serum free medium for each time point.
Selected colocalizations of NP and lysosomes are indicated by the white arrows.
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Colocalization of untargeted NP with lysosomes was greatly decreased compared to ICAM-1
targeted NP. Selected colocalizations of NP and lysosomes are indicated by the white arrows.
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(A) The colocalization of doxorubicin HCl and the nuclei was observed at 1 hr after incubation
of the drug with cells. (B) The colocalization of doxorubicin released from cLABL-DOX-NP
was observed at 1 hr but with a less extent compared to free drug. (C) The released doxorubicin
from untargeted NP localized in the nuclei was observed at 3 hr. The white arrow indicates the
colocalization.
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(A), Colocalization of doxorubicin co-encapsulated with coumarin-6 in cLABL-DOX-NP (B)
Colocalization of doxorubicin co-encapsulated with coumarin-6 in DOX-NP. The white arrow
indicates the colocalization of coumarin-6 and doxorubicin.
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The release of doxorubicin from cLABL-NP began with an initial burst of 35.2±1.7% and 34.1
± 2.8% at pH 4 (□) and pH 7.4(△), respectively, in the first three hours of the study. Data
represented mean ± S.D. (n=3).
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Table 2






PLGA 0.22 dl/g 51 ± 1.2 33 ± 5.0 41 ± 4.8 19 ± 2.1
PLGA 0.67dl/g 60 ± 2.4 37 ± 1.3 51 ± 7.6 27 ± 5.4
Values are representative of three determinations (mean ± S.D.)
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Table 3
Density of cLABL on the surface of PLGA nanoparticles




PLGA 0.22 dl/g 243 18.4 55 ± 0.8
PLGA 0.67dl/g 241 18.6 51 ± 2.1
Values are representative of three determinations (mean ± S.D.)
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